The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes - PubMed (original) (raw)

. 2001 Sep 15;61(18):6846-50.

Affiliations

PMID: 11559560

The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes

P Brossart et al. Cancer Res. 2001.

Abstract

The epithelial mucin MUC1 is overexpressed on the cell surface of many epithelial malignancies as well as on some B-cell lymphomas and multiple myelomas. Recently, we identified two HLA-A2-restricted T-cell epitopes derived from the MUC1 protein. To further extend the potential application of these peptides, we analyzed the expression of MUC1 on blast cells from patients with acute myelogenous leukemia (AML; n = 43) and several other hematological malignancies including acute lymphoblastic leukemia (n = 24), chronic lymphocytic leukemia (n = 36), hairy cell leukemia (n = 9), follicular lymphoma (n = 7), and multiple myeloma (n = 12). Using reverse transcription-PCR and MUC1-specific monoclonal antibodies, MUC1 expression was found in 67% of AML samples and 92% of myeloma samples. To analyze the presentation of MUC1 peptides by primary AML blasts, we induced MUC1-specific CTLs in vitro using peptide-pulsed dendritic cells from HLA-A2+ healthy donors as antigen-presenting cells. These CTLs efficiently lysed in an antigen-specific and HLA-A2-restricted manner not only target cells pulsed with the antigenic peptide but also tumor cell lines including multiple myeloma cells and primary AML blasts that constitutively expressed both MUC1 and HLA-A2. The specificity of the CTLs was confirmed in a cold target inhibition assay. Our data demonstrate that MUC1-derived peptides are tumor antigens in AML and several other hematological malignancies that could potentially be used for immunotherapeutic approaches.

PubMed Disclaimer

Cited by

Precision glycocalyx editing as a strategy for cancer immunotherapy.
Xiao H, Woods EC, Vukojicic P, Bertozzi CR. Xiao H, et al. Proc Natl Acad Sci U S A. 2016 Sep 13;113(37):10304-9. doi: 10.1073/pnas.1608069113. Epub 2016 Aug 22. Proc Natl Acad Sci U S A. 2016. PMID: 27551071 Free PMC article.
Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma.
Jain S, Stroopinsky D, Yin L, Rosenblatt J, Alam M, Bhargava P, Clark RA, Kupper TS, Palmer K, Coll MD, Rajabi H, Pyzer A, Bar-Natan M, Luptakova K, Arnason J, Joyce R, Kufe D, Avigan D. Jain S, et al. Blood. 2015 Jul 16;126(3):354-62. doi: 10.1182/blood-2015-02-628149. Epub 2015 Jun 5. Blood. 2015. PMID: 26048911 Free PMC article.
Design, Synthesis, and Preliminary Immunological Studies of MUC1-Based Antitumor Vaccines Adjuvanted with _R_- and _S_-FSL-1.
Liu Y, Yan B, Wang Z, Zhu H, Yin X, Wang K, Wang M, Zhao W. Liu Y, et al. ACS Med Chem Lett. 2020 Jun 22;11(7):1371-1376. doi: 10.1021/acsmedchemlett.9b00579. eCollection 2020 Jul 9. ACS Med Chem Lett. 2020. PMID: 32676142 Free PMC article.
Host tissue determinants of tumour immunity.
Salmon H, Remark R, Gnjatic S, Merad M. Salmon H, et al. Nat Rev Cancer. 2019 Apr;19(4):215-227. doi: 10.1038/s41568-019-0125-9. Nat Rev Cancer. 2019. PMID: 30867580 Free PMC article. Review.
PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine.
Rosenblatt J, Glotzbecker B, Mills H, Vasir B, Tzachanis D, Levine JD, Joyce RM, Wellenstein K, Keefe W, Schickler M, Rotem-Yehudar R, Kufe D, Avigan D. Rosenblatt J, et al. J Immunother. 2011 Jun;34(5):409-18. doi: 10.1097/CJI.0b013e31821ca6ce. J Immunother. 2011. PMID: 21577144 Free PMC article.

The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes - PubMed (original) (raw)